StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$6.65+0.95 (+16.67%)

Close on Nov 18, 2026Market cap $12.95MP/E –Yield –

Akari Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Akari Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$30.99M. For fiscal 2025 it was -$17.28M. The highest annual figure on record is -$792.00K in fiscal 2010.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.28M–
FY2024Dec 31, 2024-$21.64M–
FY2023Dec 31, 2023-$16.81M–
FY2022Dec 31, 2022-$23.09M–
FY2021Dec 31, 2021-$17.21M–
FY2020Dec 31, 2020-$17.98M–
FY2019Dec 31, 2019-$16.96M–
FY2018Dec 31, 2018-$20.79M–
FY2017Dec 31, 2017-$37.78M–
FY2016Dec 31, 2016-$27.25M–
FY2015Dec 31, 2015-$30.58M–
FY2014Dec 31, 2014-$1.92M–
FY2013Dec 31, 2013-$3.61M–
FY2012Dec 31, 2012-$3.67M–
FY2011Dec 31, 2011-$2.25M–
FY2010Dec 31, 2010-$792.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.60M–
Q1 FY2026Mar 31, 2026-$15.76M–
Q4 FY2025Dec 31, 2025-$3.23M–
Q3 FY2025Sep 30, 2025-$7.40M–
Q2 FY2025Jun 30, 2025-$3.12M–
Q1 FY2025Mar 31, 2025-$3.53M–
Q4 FY2024Dec 31, 2024-$5.28M–
Q3 FY2024Sep 30, 2024-$2.93M–
Q2 FY2024Jun 30, 2024-$7.45M–
Q1 FY2024Mar 31, 2024-$5.99M–
Q4 FY2023Dec 31, 2023-$5.09M–
Q3 FY2023Sep 30, 2023-$2.51M–
Q2 FY2023Jun 30, 2023-$4.62M–
Q1 FY2023Mar 31, 2023-$4.59M–
Q2 FY2022Jun 30, 2022-$5.82M–
Q2 FY2021Jun 30, 2021-$4.33M–
Q4 FY2020Dec 31, 2020-$6.90M–
Q3 FY2020Sep 30, 2020-$246.88K–
Q2 FY2020Jun 30, 2020-$5.91M–
Q1 FY2020Mar 31, 2020-$4.93M-41288.5%
Q4 FY2019Dec 31, 2019-$7.83M–
Q3 FY2019Sep 30, 2019-$3.12M–
Q2 FY2019Jun 30, 2019-$6.03M–
Q1 FY2019Mar 31, 2019$11.96K–
Q2 FY2018Jun 30, 2018-$7.98M–
Q2 FY2017Jun 30, 2017-$7.35M–
Q2 FY2016Jun 30, 2016-$7.52M–
Q1 FY2016Mar 31, 2016-$3.85M–
Q4 FY2015Dec 31, 2015-$4.29M–
Q3 FY2015Sep 30, 2015-$23.33M–
Q2 FY2015Jun 30, 2015-$1.31M–
Q1 FY2015Mar 31, 2015-$1.65M–
Q4 FY2014Dec 31, 2014-$1.11M–
Q3 FY2014Sep 30, 2014-$218.03K–
Q2 FY2014Jun 30, 2014-$2.33M–

More Akari Therapeutics figures

See a number that looks wrong?